



Company hosts medical symposium on bacterial pneumonia and antibiotic resistance at the 64th Annual Meeting of the German Society for Hygiene and Microbiology (DGHM)



Curetis AG to Present Its Unyvero™ Solution at DGHM Conference

(Holzgerlingen, Germany, September 19, 2012)

Curetis AG today announced the presentation of its Unyvero™ Solution for the rapid molecular diagnosis of infectious diseases and the Unyvero™ P50 Pneumonia Cartridge during the 64th Annual Meeting of the German Society for Hygiene and Microbiology (DGHM) in Hamburg.

The showcasing will be accompanied by a medical symposium with microbiology and clinical key opinion leaders, who will discuss the medical need for rapid molecular diagnostics of pneumonia pathogens and their antibiotic resistances. The symposium will provide an opportunity to discuss the potential and challenges of novel molecular diagnostics solutions in pneumonia with thought leaders from various German university clinics. Curetis will also present two posters. One will deal with extended-spectrum beta-lactam resistance in Enterobacteriaceae, the other will introduce a novel universal lysis method for body fluids suitable for molecular analysis.

"Following the introduction of the Unyvero Solution in April this year in London during the European Congress of Clinical Microbiology and Infectious Diseases, we have seen tremendous interest and excitement in the medical community," said Oliver Schacht, CEO of Curetis. "We therefore take the opportunity of this year's DGHM meeting to present and discuss the clinical and potential economic benefits of our easy-to-use, rapid molecular diagnostics platform, which offers the detection of 17 pathogens and 22 antibiotic resistance markers within a few hours rather than several days."

The symposium hosted by Curetis will take place on October 1, 2012, from 3:45pm to 4:45pm in Hall 6, Congress Center Hamburg (CCH) during the 64th Annual Meeting of the German Society for Hygiene and Microbiology (DGHM) in Hamburg (Sept. 30, - Oct. 3, 2012, CCH). Symposium speakers will be Prof. Dr. Mathias Pletz (University of Jena), Dr. Jan Weile (University of Bochum), Dr. Peter Keller (University of Jena), and Dr. Berit Schulte (University of Tuebingen). Talks will be followed by a closing discussion on the benefit of faster molecular testing moderated by Dr. Stefan Zimmermann (University of Heidelberg) and Dr. Anne Thews (Curetis AG).

Curetis AG
Max-Eyth-Str. 42
71088 Holzgerlingen
Germany
Tel. +49 (7031) 49195-10
Fax +49 (7031) 49195-19
pr@curetis.com
www.curetis.com

1



Press Release



The posters will be presented in the industrial exhibition hall (Hall 3, EGF) at CCH during Postersession II (Oct. 2, 3-4:30pm). Poster 231/KMP17 ("Extended Spectrum Beta-Lactam resistance in Enterobacteriaceae") will be presented in the section Clinical Microbiology and Infectiology (KM), Poster 232/DMP10 ("A novel universal lysis method for bodily fluids for molecular analysis") in the section Diagnostic Microbiology and MiQs (QS/DV/MiQ).

In addition, the Unyvero™ Solution will be shown in action at the conference in booth 30/31.

Curetis is proud to be Silver Sponsor of this year's Annual Meeting of the German Society for Hygiene and Microbiology (DGHM).

About the Unyvero™ System

The CE-marked Unyvero™ System is a versatile hardware platform for the detection of a broad panel of bacteria and antibiotic resistances from a single sample in one run. It processes a disposable cartridge providing the necessary reagents to complete the analysis from sample to result.

The platform enables the DNA-based testing of all clinically relevant samples in a fully automated, unsupervised analysis process requiring only few, quick manual preparation steps. The analysis thus can be performed with minimal operator time and without the need of skilled staff or special infrastructure.

Thereby, clinically relevant information is available within about four hours to support an informed therapy decision as early as possible.

The first CE-marked Unyvero™ Cartridge, Unyvero™ P50, focuses on pneumonia testing and simultaneously analyses 39 DNA targets. Cartridges for further applications, e.g. for implant & tissue infections, blood stream infections and tuberculosis, are in preparation.

About Curetis AG

Founded in 2007, Curetis AG is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis AG will enable rapid multiparameter pathogen and antibiotic resistance detection in only a few hours, a process that today can take up to days or even weeks with other techniques.

To date, Curetis has raised total funds of over € 36.6 million (~ USD 50 million) and has signed global collaboration agreements with Sanofi Pasteur and Cempra Inc. as well as several international distribution agreements for its Unyvero[™] Solution. The company is based in Holzgerlingen near Stuttgart, Germany.

Curetis AG
Max-Eyth-Str. 42
71088 Holzgerlingen
Germany
Tel. +49 (7031) 49195-10
Fax +49 (7031) 49195-19
pr@curetis.com
www.curetis.com





Contact

Curetis AG Max-Eyth-Str. 42 71088 Holzgerlingen, Germany

Tel. +49 (7031) 49195-10 pr@curetis.com www.curetis.com

Media Inquiries:

akampion Dr. Ludger Wess / Ines-Regina Buth Managing Partners

info@akampion.com Tel. +49 40 88 16 59 64 Tel. +49 30 23 63 27 68

Curetis AG
Max-Eyth-Str. 42
71088 Holzgerlingen
Germany
Tel. +49 (7031) 49195-10
Fax +49 (7031) 49195-19
pr@curetis.com
www.curetis.com